Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026
Same author

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026
Same author

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Blood advances·2026

Related Experiment Video

Updated: Mar 24, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

Lenalidomide plus Rituximab for Mantle-Cell Lymphoma

Jia Ruan, John P Leonard

    The New England Journal of Medicine
    |March 3, 2016
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
    08:31

    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

    Published on: September 12, 2025

    991

    Related Experiment Videos

    Last Updated: Mar 24, 2026

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
    10:52

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

    Published on: March 30, 2018

    11.7K
    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
    08:31

    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

    Published on: September 12, 2025

    991